Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database

Naoto Okada1 | Takahiro Niimura2 | Yoshito Zamami1,2 | Hirofumi Hamano1 | Shunsuke Ishida1 | Mitsuhiro Goda1 | Kenshi Takechi3 | Masayuki Chuma3 | Masaki Imanishi1 | Keisuke Ishizawa1,2

Abstract
Breakpoint cluster region-Abelson murine leukemia (BCR-ABL) inhibitors markedly improve the prognosis of chronic myeloid leukemia. However, high treatment adherence is necessary for successful treatment with BCR-ABL inhibitors. Therefore, an adequate understanding of the adverse event profiles of BCR-ABL inhibitors is essential. Although many adverse events are observed in trials, an accurate identification of adverse events based only on clinical trial results is difficult because of strict entry criteria or limited follow-up durations. In particular, BCR-ABL inhibitor-induced impaired glucose metabolism remains controversial. Pharmacovigilance evaluations using spontaneous reporting systems are useful for analyzing drug-related adverse events in clinical settings. Therefore, we conducted signal detection analyses for BCR-ABL inhibitor-induced impaired glucose metabolism by using the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) database. Signals for an increased reporting rate of impaired glucose metabolism were detected only for nilotinib use, whereas these signals were not detected for other BCR-ABL inhibitors. Subgroup analyses showed a clearly increased nilotinib-associated reporting rate of impaired glucose metabolism in male and younger patients. Although FAERS- and JADER-based signal detection analyses cannot determine causality perfectly, our study suggests the effects on glucose metabolism are different between BCR-ABL inhibitors and provides useful information for the selection of appropriate BCR-ABL inhibitors.

KEYWORDS
BCR-ABL inhibitors, FAERS, impaired glucose metabolism, JADER, spontaneous reporting system

Naoto Okada and Takahiro Niimura are contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Chronic myeloid leukemia (CML) is a clonal stem cell neoplasm characterized by the presence of the Philadelphia (Ph) chromosome.1 The Ph chromosome produces the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion protein, which dysregulates tyrosine kinase activity and induces uncontrolled proliferation of the granulocyte lineage. Imatinib, nilotinib, dasatinib, bosutinib, and ponatinib are tyrosine kinase inhibitors that inhibit the activity of the BCR-ABL fusion protein. These BCR-ABL inhibitors have been reported to improve markedly the prognosis of CML.2-6 However, maintaining high therapeutic adherence is necessary to obtain the maximum therapeutic effect with BCR-ABL inhibitors.7 For instance, an adequate blood concentration of imatinib is necessary to obtain the maximum therapeutic effect.8 However, adverse events induced by BCR-ABL inhibitors decrease therapeutic adherence. Therefore, a good understanding of the adverse event profile of BCR-ABL inhibitors is essential for successful CML treatment.

Adverse events related to a class effect or a drug effect of BCR-ABL inhibitors have been observed in clinical trials. Cardiovascular toxicity was reported as a common adverse event induced by all BCR-ABL inhibitors,9 while impaired glucose metabolism was reported in cases of nilotinib use.10-12 Impaired glucose metabolism increases the risk of cardiovascular events and limits the patients who can receive nilotinib treatment. Furthermore, these adverse events decrease patient adherence to BCR-ABL inhibitors. However, there have been no reports related to impaired glucose metabolism caused by imatinib or dasatinib. Imatinib, in fact, has been reported to facilitate the recovery of glucose metabolism.13-15 However, because these findings were reported in case reports or studies with low reliability, the effects of BCR-ABL inhibitors on glucose metabolism remain controversial, and there is no choice but to treat this adverse event empirically. Therefore, it is important to understand this adverse event induced by BCR-ABL inhibitors to promote their proper use. Several studies have indicated that the safety data provided by clinical trials do not reflect data from real clinical settings because of strict entry criteria or limited follow-up durations.9 The long-term follow-up data, including the data of patients with various comorbidities in real clinical settings, are essential for understanding the accurate impact of BCR-ABL inhibitors on glucose metabolism. However, these analyses were rarely conducted and the detailed characteristics of this adverse event remain unclear.

In recent years, spontaneous reporting systems (SRS) reflecting data from actual clinical practice have been used to evaluate drug safety. The US Food and Drug Administration (FDA) manages the FDA Adverse Event Reporting System (FAERS), which has registered more than three million spontaneous reports of adverse events and is the largest SRS database in the world.16 In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) manages the Japanese Adverse Drug Event Report (JADER) database, which has registered approximately 300 000 spontaneous reports of adverse events.17 These databases are publically available and reflect full adverse event profiles in real clinical settings. Therefore, these databases are used in pharmacovigilance analyses and are useful for evaluating the risk of adverse events reflected in real clinical settings.18-21

The aim of this study was to analyze the relationship between BCR-ABL inhibitors and impaired glucose metabolism using FAERS and the JADER database. We also evaluated the characteristics of impaired glucose metabolism induced by BCR-ABL inhibitors.

2 | MATERIAL AND METHODS

2.1 | Database source

Adverse event reports were downloaded from the FDA and PMDA websites.22,23 JADER data until May 2017, which are publicly available on the PMDA website, were used. For FAERS analysis, data from the third quarter of 2010 to the second quarter of 2015 were used. Because FAERS includes duplicate reports, only the latest report of a patient was used for analysis according to the recommendation of the FDA.24 Only reports with complete age and sex information were extracted. Furthermore, we analyzed reports with patient ages greater than 20 years in this analysis. Supplemental analysis using all reports was also performed. Reporting odds ratios (RORs) were used for evaluating signal detection. Each case was divided into four groups based on whether “Impaired glucose metabolism” developed and whether a BCR-ABL inhibitor was used. Namely, there were (n11) cases who used a BCR-ABL inhibitor and reported as “Impaired glucose metabolism,” (n12) cases who used a BCR-ABL inhibitor and did not report as “Impaired glucose metabolism,” (n21) cases who did not use a BCR-ABL inhibitor and reported as “Impaired glucose metabolism,” and (n22) cases who did not use a BCR-ABL inhibitor and did not report as “Impaired glucose metabolism.” The ROR and 95% confidence interval (CI) were calculated by the following formula.24

$$ROR = \frac{n_11/n_21}{n_12/n_22}, \quad 95% \ CI = exp\{\log (ROR) \pm 1.96 \sqrt{\frac{1}{n_11} + \frac{1}{n_12} + \frac{1}{n_21} + \frac{1}{n_22}}\}$$

A signal was considered detected when the lower limit of the 95% CI of the ROR exceeded one. In the subgroup analysis in JADER, reports were analyzed as 10-year
subgroups because age was described in 10-year increments. Additionally, time-onset analysis was performed using the drug administration start date and the adverse event occurrence date included in the JADER database. The downloaded data were processed using Microsoft Access 2016® (Microsoft, Redmond, WA). All data analyses were performed in more than two independent experiments.

2.2 | Outcomes

In JADER and FAERS, the descriptions of adverse event names conform to the Medical Dictionary for Regulatory Activities (MedDRA) developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Therefore, the adverse events that were defined using MedDRA conformed to the adverse event names in our study. Impaired glucose metabolism is defined by 113 preferred terms that were included in the standardized MedDRA queries “hyperglycemia/new onset diabetes mellitus” (SMQ 20000041).

2.3 | Statistical analysis

Categorical variables are summarized in terms of frequencies and percentages. The Fisher exact test was used to compare the frequency of adverse events in the presence or absence of BCR-ABL inhibitors. Days from the administration of nilotinib to the onset of impaired glucose metabolism in nilotinib-administered patients were analyzed by the Kaplan-Meier method. The analyses were performed using R statistical software version 3.3.2. Statistical significance was defined as a P-value <0.05.

3 | RESULTS

3.1 | Reporting rate of impaired glucose metabolism reported in FAERS and the JADER database

In FAERS, 572, 306, 514, 42, and 114 cases of impaired glucose metabolism associated with imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, respectively, were reported (Table 1). In the JADER database, 75, 23, 93, and three cases of impaired glucose metabolism associated with imatinib, dasatinib, nilotinib, and bosutinib, respectively, were reported. No cases associated with ponatinib were reported in the JADER database. The ROR of impaired glucose metabolism associated with nilotinib was 1.26 (95% CI: 1.149-1.382) in FAERS and 1.32 (95% CI: 1.059-1.634) in the JADER database, and signals for an increased reporting rate of impaired glucose metabolism were detected (P < 0.001). In contrast, the RORs of impaired glucose metabolism associated with imatinib and dasatinib were 0.79 (95% CI: 0.722-0.857) and 0.80 (95% CI: 0.708-0.896), respectively, in FAERS and 0.40 (95% CI: 0.313-0.503) and 0.41 (95% CI: 0.261-0.625), respectively, in the JADER database; signals for an increased reporting rate of impaired glucose metabolism were not detected. These signals were also not detected for bosutinib (ROR: 0.64, 95% CI: 0.459-0.876) and ponatinib (ROR: 1.10, 95% CI: 0.900-1.335) in the FAERS database.

3.2 | Relationship between impaired glucose metabolism and sex

In FAERS, signals for an increased reporting rate of impaired glucose metabolism were detected for nilotinib regardless of sex (male: ROR, 1.23, 95% CI, 1.088-1.394; female: ROR, 1.28, 95% CI, 1.107-1.466) (Table 2). In the JADER database, signals for an increased reporting rate of impaired glucose metabolism were not detected for nilotinib regardless of sex (male: ROR, 1.23, 95% CI, 1.088-1.394; female: ROR, 1.28, 95% CI, 1.107-1.466) (Table 2). In the JADER database,

| Drug A | Impaired glucose metabolism without Drug A | Impaired glucose metabolism with Drug A | ROR | 95% CI | P value |
|--------|------------------------------------------|----------------------------------------|------|--------|---------|
| **FAERS** | | | | | |
| Imatinib | 176 388/2 167 224 (8.86%) | 572/8771 (6.52%) | 0.79 | 0.722-0.857 | <0.001 |
| Dasatinib | 176 654/2 171 358 (8.86%) | 306/4637 (6.6%) | 0.80 | 0.708-0.896 | <0.001 |
| Nilotinib | 176 446/2 170 873 (8.85%) | 514/5122 (10.04%) | 1.26 | 1.149-1.382 | <0.001 |
| Bosutinib | 176 918/2 175 214 (8.85%) | 42/781 (5.38%) | 0.64 | 0.459-0.876 | 0.004 |
| Ponatinib | 176 846/2 174 711 (8.85%) | 114/1284 (8.88%) | 1.1 | 0.9-1.335 | 0.332 |
| **JADER** | | | | | |
| Imatinib | 20 064/378 563 (5.6%) | 75/3429 (2.19%) | 0.40 | 0.313-0.503 | <0.001 |
| Dasatinib | 20 116/380 973 (5.57%) | 23/1019 (2.26%) | 0.41 | 0.261-0.625 | <0.001 |
| Nilotinib | 20 046/380 634 (5.56%) | 93/1358 (6.85%) | 1.32 | 1.059-1.634 | 0.012 |
| Bosutinib | 20 136/381 868 (5.57%) | 3/124 (2.42%) | 0.45 | 0.091-1.333 | 0.223 |

CI, confidence interval; FAERS, Food and Drug Administration Adverse Event Reporting System; JADER, Japanese Adverse Drug Event Report; ROR, reporting odds ratio.
OKADA et al.

### 3.3 Relationship between impaired glucose metabolism and age

In FAERS, signals for an increased reporting rate of impaired glucose metabolism were detected in only the male groups treated with nilotinib (male: ROR, 1.37, 95% CI, 1.034-1.783; female: ROR, 1.23, 95% CI, 0.839-1.757). These signals were not detected for other BCR-ABL inhibitors regardless of sex.

#### Table 2 Effect of sex on impaired glucose metabolism reported in FAERS and the JADER database

| Drug A | Impaired glucose metabolism without Drug A | Impaired glucose metabolism with Drug A | ROR | 95% CI | P value |
|--------|------------------------------------------|----------------------------------------|-----|-------|---------|
| **FAERS** | | | | | |
| Male | | | | | |
| Imatinib | 67 905/815 539 (9.08%) | 266/4850 (5.48%) | 0.64 | 0.562-0.723 | <0.001 |
| Dasatinib | 68 023/818 027 (9.07%) | 148/2362 (6.27%) | 0.74 | 0.62-0.871 | <0.001 |
| Nilotinib | 67 882/817 513 (9.06%) | 289/2876 (10.05%) | 1.23 | 1.088-1.394 | 0.001 |
| Bosutinib | 68 151/820 016 (9.06%) | 20/373 (5.36%) | 0.63 | 0.377-0.98 | 0.039 |
| Ponatinib | 68 115/819 727 (9.06%) | 56/662 (8.46%) | 1.02 | 0.761-1.342 | 0.888 |
| Female | | | | | |
| Imatinib | 108 483/1 351 685 (8.73%) | 306/3921 (7.8%) | 0.97 | 0.86-1.091 | 0.638 |
| Dasatinib | 108 631/1 353 331 (8.73%) | 158/2275 (6.95%) | 0.86 | 0.723-1.006 | 0.058 |
| Nilotinib | 108 564/1 353 360 (8.72%) | 225/2246 (10.02%) | 1.28 | 1.107-1.466 | <0.001 |
| Bosutinib | 108 767/1 355 198 (8.73%) | 22/408 (5.39%) | 0.65 | 0.405-1.003 | 0.055 |
| Ponatinib | 108 731/1 354 984 (8.72%) | 58/622 (9.32%) | 1.18 | 0.883-1.546 | 0.237 |
| **JADER** | | | | | |
| Male | | | | | |
| Imatinib | 10 395/192 651 (5.7%) | 35/1926 (1.82%) | 0.32 | 0.225-0.453 | <0.001 |
| Dasatinib | 10 418/194 001 (5.67%) | 12/576 (2.08%) | 0.37 | 0.193-0.66 | <0.001 |
| Nilotinib | 10 370/193 742 (5.66%) | 60/835 (7.19%) | 1.37 | 1.034-1.783 | 0.025 |
| Bosutinib | 10 427/194 499 (5.66%) | 3/78 (3.85%) | 0.71 | 0.142-2.145 | 0.800 |
| Female | | | | | |
| Imatinib | 9669/185 912 (5.49%) | 40/1503 (2.66%) | 0.5 | 0.354-0.682 | <0.001 |
| Dasatinib | 9698/186 972 (5.47%) | 11/443 (2.48%) | 0.47 | 0.231-0.842 | 0.007 |
| Nilotinib | 9676/186 892 (5.46%) | 33/523 (6.31%) | 1.23 | 0.839-1.757 | 0.235 |
| Bosutinib | 7162/157 401 (4.77%) | 0/41 (0%) | - | - | - |

CI, confidence interval; FAERS, Food and Drug Administration Adverse Event Reporting System; JADER, Japanese Adverse Drug Event Report; ROR, reporting odds ratio.

#### Table 3 Time-onset analysis of impaired glucose metabolism using the JADER database

The time-onset analysis showed that the reports of impaired glucose metabolism induced by nilotinib increased within 200 days. However, late-onset events beyond 600 days were also reported (Figure 1).

#### 4 Discussion

Our analyses using FAERS and the JADER database revealed that signals for an increased reporting rate were detected only for nilotinib. These signals were clearly detected in male or younger patients. However, these signals were not detected for other BCR-ABL inhibitors.

Our study showed the relationship between nilotinib and the increased reporting rate of impaired glucose metabolism. However, the mechanism of impaired glucose metabolism remains to be elucidated.
metabolism induced by nilotinib remains unclear. Some case reports have suggested that nilotinib decreases insulin sensitivity or inhibits insulin secretion, causing impaired glucose metabolism.\textsuperscript{25,26} However, because only a few studies have referred to this phenomenon, the increase in the risk of impaired glucose metabolism induced by nilotinib was evaluated empirically herein. Signals of increased reporting rate were detected for nilotinib in the analysis comprising all patient reports in FAERS, and this trend was also observed in the analysis based on the JADER database (Table S1). Therefore, this result is considered valid.

Follow-up analysis for 5 years in the patients who received nilotinib or imatinib revealed that increased glucose levels were clearly observed in nilotinib-treated patients, which is consistent with our results.\textsuperscript{27} To our knowledge, this study is the first to demonstrate the relationship between nilotinib and increased risk of impaired glucose metabolism. A reduction in the risk of cardiovascular events is necessary to maintain the quality of life during CML treatment.\textsuperscript{28} Our study suggests avoiding nilotinib treatment for patients with diabetes or other diseases that increase the risk of cardiovascular events. The time-onset analysis revealed that impaired glucose metabolism induced by nilotinib was reported at more than a year. This result highlights the importance of continuous monitoring of blood glucose levels during nilotinib treatment. The subgroup analyses revealed that the signals of increased reporting rate of impaired glucose metabolism induced by nilotinib were clearly detected in male or younger patients. BCR-ABL inhibitor treatment lasts a lifetime. Therefore, it may be better to avoid nilotinib treatment in younger patients with a high risk of diabetes mellitus.

Decreased adherence to BCR-ABL inhibitor treatment commonly occurs.\textsuperscript{29} Although age and sex were reported as the factors for limiting adherence, adverse events induced by BCR-ABL inhibitors also decrease adherence.\textsuperscript{30} Early detection of adverse events and adequate supportive care is useful to improve adherence. Moreover, Leader et al.\textsuperscript{31} reported

\begin{table}
\centering
\begin{tabular}{|l|c|c|c|c|c|}
\hline
\textbf{Drug A} & \textbf{Impaired glucose metabolism without Drug A} & \textbf{Impaired glucose metabolism with Drug A} & \textbf{ROR} & \textbf{95\% CI} & \textbf{P value} \\
\hline
\textbf{FAERS}  &  &  &  &  &  \\
\hline
\textbf{20-60 s} &  &  &  &  &  \\
Imatinib & 132/131(1.641.998 (8.75\%)) & 393/6392 (6.15\%) & 0.75 & 0.674-0.829 & <0.001 \\
Dasatinib & 132/304/1 (645 007 (8.75\%)) & 220/3383 (6.5\%) & 0.8 & 0.69-0.912 & <0.001 \\
Nilotinib & 132/199/1 (644 856 (8.74\%)) & 325/3534 (9.2\%) & 1.16 & 1.031-1.299 & 0.013 \\
Bosutinib & 132/497/1 (647 848 (8.74\%)) & 27/542 (4.98\%) & 0.6 & 0.391-0.883 & 0.007 \\
Ponatinib & 132/444/1 (647 417 (8.74\%)) & 80/973 (8.22\%) & 1.02 & 0.805-1.289 & 0.841 \\
\hline
\textbf{70-90 s} &  &  &  &  &  \\
Imatinib & 44/257/525 227 (9.2\%) & 179/2379 (7.52\%) & 0.88 & 0.755-1.031 & 0.120 \\
Dasatinib & 44/350/526 352 (9.2\%) & 86/1254 (6.86\%) & 0.8 & 0.635-0.997 & 0.047 \\
Nilotinib & 44/247/526 018 (9.18\%) & 189/1588 (11.9\%) & 1.47 & 1.257-1.714 & <0.001 \\
Bosutinib & 44/421/527 367 (9.2\%) & 15/239 (6.28\%) & 0.73 & 0.401-1.227 & 0.293 \\
Ponatinib & 44/402/527 295 (9.19\%) & 34/311 (10.93\%) & 1.33 & 0.906-1.911 & 0.124 \\
\hline
\textbf{JADER}  &  &  &  &  &  \\
\textbf{20-60 s} &  &  &  &  &  \\
Imatinib & 10 542/223 081 (4.96\%) & 40/2088 (1.92\%) & 0.39 & 0.28-0.538 & <0.001 \\
Dasatinib & 10 565/224 491 (4.94\%) & 17/678 (2.51\%) & 0.52 & 0.301-0.841 & 0.005 \\
Nilotinib & 10 527/224 375 (4.92\%) & 55/794 (6.93\%) & 1.51 & 1.127-1.991 & 0.005 \\
Bosutinib & 10 581/225 096 (4.93\%) & 1/73 (1.37\%) & 0.28 & 0.007-1.62 & 0.265 \\
\hline
\textbf{70-90 s} &  &  &  &  &  \\
Imatinib & 9522/155 482 (6.52\%) & 35/1341 (2.61\%) & 0.41 & 0.285-0.575 & <0.001 \\
Dasatinib & 9551/156 482 (6.5\%) & 6/341 (1.76\%) & 0.28 & 0.1-0.606 & <0.001 \\
Nilotinib & 9519/156 259 (6.49\%) & 38/564 (6.74\%) & 1.11 & 0.779-1.55 & 0.536 \\
Bosutinib & 9555/156 772 (6.49\%) & 2/51 (3.92\%) & 0.63 & 0.074-2.397 & 0.770 \\
\hline
\end{tabular}
\caption{Effect of age on impaired glucose metabolism reported in FAERS and the JADER database}
\end{table}
that multidisciplinary intervention improved the adherence to BCR-ABL inhibitors. Our studies provide useful information for conducting optimal supportive care to improve this adherence.

There are some limitations associated with FAERS and the JADER database because these databases are reporting systems for spontaneous adverse events. Data from these databases were collected from various clinical settings wherein adverse event reporting was voluntary. Therefore, these databases might include duplicate data.32 We excluded duplicate data according to the recommendation of the FDA. In addition to the possibility of an over-reporting bias, an under-reporting bias, due to nonreporting of adverse events by healthcare workers, exists.32 It is known that spontaneous adverse event reports tend to increase after drug safety alerts or publications, which is called notoriety bias.33 Considering these reporting biases, caution should be exercised when interpreting results obtained from only one SRS database. In our study, we used two SRS databases, FAERS and the JADER database, to overcome reporting biases and increase the reliability of our results. FAERS is one of the largest SRS databases in the world and is suitable for analyzing the risk detection of adverse events induced by medications, owing to the large number of reports. However, this database does not include detailed data pertaining to adverse events, such as durations of medication administration and patient characteristics. In contrast, the JADER database contains detailed patient characteristics and adverse events, although the number of reports is lower than that in FAERS because the JADER database contains data from only Japanese patients. Our results have high reliability because the same results were obtained from two databases. Although we recognize the limitations associated with SRS, our study provides useful evidence showing differences in the effects on impaired glucose metabolism between BCR-ABL inhibitors.

We used RORs to detect signals of risk increase or decrease. In data mining analyses, proportional reporting ratios (PRR) and multi-item gamma Poisson Shrinker (MGPS) are used for signal detection algorithms.9,32 Although all algorithms showed high specificity, each algorithm showed different sensitivity.34 The detection sensitivity of MGPS is 26%, and we should consider overlooking risk when using MGPS-based algorithms. On the contrary, ROR and PRR have high sensitivity. Especially, ROR is usually used in signal detection algorithms due to its simplicity.17,21,24 However, ROR-based algorithms have the disadvantage of decreased detection power when the number of adverse event reports is small. The number of reports of impaired glucose metabolism related to BCR-ABL inhibitors was not small, and it was reasonable to use ROR in signal detection in our study. A high ROR indicates an increase in the risk of an adverse event report, not an increase in the risk of development of adverse events. Therefore, we are aware that an increased ROR only offers a rough indication of signal strength.

Despite the inherent limitations of signal detection using SRS databases, our results regarding the differences in the effects on impaired glucose metabolism between BCR-ABL inhibitors are in agreement with the results of previous studies. Thus, our study provides beneficial information for the management of adverse events induced by BCR-ABL inhibitors.

5 | CONCLUSION

Our study using FAERS and the JADER database revealed that the use of nilotinib increased the reporting rate of impaired glucose metabolism, whereas other BCR-ABL inhibitors did not increase reports of this adverse event. This finding indicated that only nilotinib increased the risk of impaired glucose tolerance and that adverse events might be drug effects of nilotinib and not class effects of BCR-ABL inhibitors. Although further analyses are required to confirm these findings, our results indicated differences in the effect on glucose metabolism between BCR-ABL inhibitors and that careful monitoring of glucose levels is necessary among nilotinib-treated patients.

CONFLICT OF INTEREST

The authors have indicated that they have no conflicts of interest regarding the content of this article.

ORCID

Naoto Okada https://orcid.org/0000-0003-2476-9191
REFERENCES

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042.

2. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.

3. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.

4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.

5. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. 2001;344(14):1038-1042.

6. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576.

7. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determination, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.

8. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27(19):3141-3147.

9. Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90(4):E66-E72.

10. Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013;98(10):e124-e126.

11. Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6(32):33944-33951.

12. Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31(12):1770-1772.

13. Ono K, Suzushima H, Watanabe Y, et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Int Med. 2012;51(19):2763-2766.

14. Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32(10):1626-1628.

15. Agostoni NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17(3):197-202.

16. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539-546.

17. Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y. Influence of Japanese regulatory action on denosumab-related hypocalcemia using Japanese adverse drug event report database. Biol Pharm Bull. 2017;40(9):1447-1453.

18. Welch HK, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the united states food and drug administration adverse event reporting system database. Pharmacotherapy. 2018;38(8):785-793.

19. Sanagawa A, Hotta Y, Kataoka T, et al. Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA adverse event reporting system. Cancer Med. 2018;7(6):2269-2279.

20. Noguchi Y, Katsuno H, Ueno A, et al. Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. J Pharm Health Care Sci. 2018;4:15.

21. Fukuda A, Tahara K, Hane Y, et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS ONE. 2017;12(9):e0185654.

22. US Food and Drug Administration. FDA Adverse Event Reporting System web site. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed June 5, 2018.

23. Pharmaceuticals and Medical Devices Agency. Japanese Adverse Drug Event Report database web site. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0003.html. Accessed June 5, 2018.

24. Suzuki Y, Suzuki H, Umetu R, et al. Analysis of the interaction between clopidogrel, aspirin, and proton pump inhibitors using the FDA adverse event reporting system database. Biol Pharm Bull. 2015;38(5):680-686.

25. Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013;97(1):135-138.

26. Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res. 2012;36(4):e66-e67.

27. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. leukemia. 2016;30(5):1044-1054.

28. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625-632.

29. Rychter A, Jerzmanowski P, Holub A, et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017;34(6):104.

30. Jabbour EJ, Kantarjian H, Eliaslon L, Cornelison AM, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87(7):687-691.
31. Leader A, Benyamini N, Gafter-Gvili A, et al. Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a quasi-experimental pre-post intervention multicenter pilot study. Clin Lymphoma Myeloma Leuk. 2018;18(11):e449-e461.

32. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427-436.

33. de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Drame M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23(9):989-992.

34. Matsushita Y, Kuroda Y, Niwa S, Sonohara S, Hamada C, Yoshimura I. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer. Drug Saf. 2007;30(8):715-726.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Okada N, Niimura T, Zamami Y, et al. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. Cancer Med. 2019;8:174–181. https://doi.org/10.1002/cam4.1920